Brilinta’s PhIII THEMIS trial met primary endpoint
25 February 2019 07:00 GMT Brilinta's Phase III THEMIS trial met primary endpoint in patients with established coronary artery disease and type-2 diabetes Brilinta reduced cardiovascular events in patients with no prior heart attack or stroke The Phase III THEMIS trial met its primary endpoint and demonstrated that Brilinta (ticagrelor), taken in conjunction with aspirin, showed a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE) compared to aspirin alone. THEMIS was conducted in over 19,000 patients with coronary artery disease (